Medtronic's diabetes care unit has grown faster than the rest of its business in recent years. Over the past few years, ...

CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech ...

The global AI in Remote Patient Monitoring Market valued at US$1551.8 million in 2023, stood at US$1,967.7 million in 2024 ...

Medtronic upgraded to 'Strong Buy' with $104 fair value. Diabetes spin-off boosts focus on core markets, driving growth, ...

Medtronic’s move to turn its diabetes division into a separate company allows it to step away from a lower-profit, ...

Medtronic plc revealed plans to spin off its underperforming diabetes unit as a separate public company during its fourth quarter 2025 earnings call on May 21. The company expects to complete the ...

the company is also seeking approval of an all-in-one diabetes management system that would pair a Medtronic insulin pump and dosing algorithm with Abbott’s continuous glucose monitor technology ...

On the other hand, CGMs offer continuous, real-time monitoring, allowing users to track trends ... Like other CGMs, it uses interstitial fluids to measure blood glucose. Unlike Dexcom and Medtronic, ...

Medicare might cover other continuous glucose monitors approved by the FDA, such as the Dexcom G6 and Medtronic Guardian. Generally, Medicare also covers fingerstick monitors and those ...

Medtronic arguably enjoys more accurate ... many patients (especially type 1 diabetes patients) pair it with a continuous glucose monitor to provide real-time readings on a smartphone or smartwatch.

Medtronic announced plans to spin off its once-strained but now-growing diabetes business into an independent company, allowing the medtech giant to focus on high-growth markets such as pulsed field ...

The global insulin pumps market, valued at USD 5.5 billion in 2022, is poised for remarkable growth, with an anticipated compound annual growth rate (CAGR) of 10.3% from 2022 to 2032, according to a ...